Managing the perioperative patient on direct oral anticoagulants;La prise en charge du patient périopératoire sous anticoagulants oraux directs

Canadian Journal of Anesthesia

Volumn 64, Issue 6, 2017, Pages 656-672

  Leitch, Jordan ^a   van Vlymen, Janet ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; ANDEXANET ALFA; ANTICOAGULANT AGENT; APIXABAN; CIRAPARANTAG; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; HEPARIN; IDARUCIZUMAB; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TRANEXAMIC ACID; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; ELECTIVE SURGERY; EMBOLISM; EMERGENCY SURGERY; END STAGE RENAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMODIALYSIS; HUMAN; LOW DRUG DOSE; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBIN TIME; VENOUS THROMBOEMBOLISM; ANESTHESIOLOGY; CHEMICALLY INDUCED; COMPLICATION; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANESTHESIOLOGY; ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; PERIOPERATIVE CARE; STROKE; VENOUS THROMBOEMBOLISM;

EID: 85018509972     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-017-0868-2     Document Type: Article

References (27)

1. Weitz JI, Semchuk W, Turpie AG, et al. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. Clin Ther 2015; 37: 2506-14.
2. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012; 28: 125-36.
3. Hanley CM, Kowey PR. Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? J Thorac Dis 2015; 7: 165-71.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
5. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-73.
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
7. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
8. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.
9. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120: 2954-62.
10. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35: 64-101. Interim update available from URL: https://www.asra.com/advisory-guidelines/article/1/anticoagulation-3rd-edition (accessed January 2017).
11. Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of. Pain. 2015; 40: 182-212.
12. Beyer-Westendorf J, Michalski F, Thieme C, Tittl L. Effectiveness, safety and management of novel direct oral anticoagulants in daily care - Updated results of the prospective Dresden noac registry (NCT01588119). J Thromb Haemost 2014; 12(Suppl. 1): A21 (abstract).
13. Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. J Thromb Haemost 2015; 113: 625-32.
14. Liew A, Douketis J. Perioperative management of patients who are receiving a novel oral anticoagulant. Intern Emerg Med 2013; 8: 477-84.
15. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118: 1466-74.
16. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64: 1128-39.
17. Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Haematol 2016; 173: 37-48.
18. Lai A, Davidson N, Galloway SW, Thachil J. Perioperative management of patients on new oral anticoagulants. Br J Surg 2014; 101: 742-9.
19. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag 2016; 12: 35-44.
20. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014; 14: 147-54.
21. Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost 2015; 13: 1790-8.
22. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-9.
23. Levi M, Moore KT, Castillejos CF, et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12: 1428-36.
24. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. J Thromb Haemost 2012; 108: 217-24.
25. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511-20.
26. Connolly SJ Jr, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375: 1131-41.
27. Laulicht B, Bakhru S, Lee C, et al. Small molecule antidote for anticoagulants. Circulation 2012; 126: A11395 (abstract).